| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erika Hubina, László Kovács, Zoltán Görömbey, István Szabolcs, Sándor Czirják, Miklós I Gót. Thyrotropin secretion during oral glucose tolerance test in acromegalic patients and control subjects. Endocrine. vol 22. issue 2. 2004-07-20. PMID:14665723. |
abnormal growth hormone secretory pattern to glucose load is characteristic of acromegaly, and it might reflect alterations in somatostatin release. |
2004-07-20 |
2023-08-12 |
human |
| Erika Hubina, László Kovács, Zoltán Görömbey, István Szabolcs, Sándor Czirják, Miklós I Gót. Thyrotropin secretion during oral glucose tolerance test in acromegalic patients and control subjects. Endocrine. vol 22. issue 2. 2004-07-20. PMID:14665723. |
we evaluated the sensitivity of serum thyrotropin response to presumed somatostatin inhibition during oral glucose tolerance test in 29 patients with active acromegaly, in 13 patients with inactive disease, and in 19 control persons suspected of impaired glucose tolerance. |
2004-07-20 |
2023-08-12 |
human |
| Erika Hubina, László Kovács, Zoltán Görömbey, István Szabolcs, Sándor Czirják, Miklós I Gót. Thyrotropin secretion during oral glucose tolerance test in acromegalic patients and control subjects. Endocrine. vol 22. issue 2. 2004-07-20. PMID:14665723. |
these data do not support the concept of decreased somatostatin drive in acromegaly. |
2004-07-20 |
2023-08-12 |
human |
| Robert D Murray, Kiwon Kim, Song-Guang Ren, Ian Lewis, Gisbert Weckbecker, Christian Bruns, Shlomo Melme. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. The Journal of clinical endocrinology and metabolism. vol 89. issue 6. 2004-07-19. PMID:15181094. |
currently available somatostatin analogs predominantly bind to the somatostatin receptor subtype (sstr)2 subtype, and control gh and igf-i secretion in approximately 65% of patients with acromegaly, their efficacy relating to receptor density and subtype expression. |
2004-07-19 |
2023-08-12 |
human |
| Angela N Paisley, Peter Trainer, William Drak. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert opinion on biological therapy. vol 4. issue 3. 2004-07-13. PMID:15006735. |
disease control is achievable with pegvisomant in patients who are wholly or partially resistant or do not tolerate somatostatin analogues; preliminary data suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus. |
2004-07-13 |
2023-08-12 |
Not clear |
| J Gilbert, M Ketchen, P Kane, T Mason, E Baister, M Monaghan, S Barr, P E Harri. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary. vol 6. issue 1. 2004-07-06. PMID:14674719. |
somatostatin analogues are normally used as adjunctive therapy to surgery and radiotherapy in management of acromegaly. |
2004-07-06 |
2023-08-12 |
Not clear |
| Ruth Mangupli, Aponte Lisette, Contreras Ivett, Camperos Paul, Cruz de los Ríos Victoria, Cevallos Jose Lui. Improvement of acromegaly after octreotide LAR treatment. Pituitary. vol 6. issue 1. 2004-07-06. PMID:14674721. |
octreotide is a somatostatin analog that inhibits growth hormone release showing higher potency than natural somatostatin so it has proved to be effective in acromegaly treatment. |
2004-07-06 |
2023-08-12 |
Not clear |
| S W van Thiel, J A Romijn, N R Biermasz, B E P M Ballieux, M Frölich, J W A Smit, E P M Corssmit, F Roelfsema, A M Pereir. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European journal of endocrinology. vol 150. issue 4. 2004-06-18. PMID:15080778. |
recently a new depot preparation of the long-acting somatostatin analogue, lanreotide autogel was introduced for the treatment of acromegaly. |
2004-06-18 |
2023-08-12 |
Not clear |
| R Baldelli, C Durante, E D'Amico, F Diacono, G Tamburrano, F F Casanuev. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. Journal of endocrinological investigation. vol 26. issue 12. 2004-06-17. PMID:15055476. |
interestingly, the typical correlation of leptin with body mass index (bmi) was not present in active acromegaly, whereas it was restored after somatostatin analogs treatment; moreover, the gender difference in leptin secretion between men and women was preserved in active and controlled acromegaly. |
2004-06-17 |
2023-08-12 |
Not clear |
| G Vitale, R Pivonello, D Ferone, M C De Martino, R S Auriemma, M Caraglia, A Abbruzzese, G Lombardi, A Cola. The role of somatostatin receptors in the medical treatment of acromegaly. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. vol 36 Suppl 1. 2004-06-01. PMID:15077912. |
the role of somatostatin receptors in the medical treatment of acromegaly. |
2004-06-01 |
2023-08-12 |
Not clear |
| G Vitale, R Pivonello, D Ferone, M C De Martino, R S Auriemma, M Caraglia, A Abbruzzese, G Lombardi, A Cola. The role of somatostatin receptors in the medical treatment of acromegaly. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. vol 36 Suppl 1. 2004-06-01. PMID:15077912. |
octreotide, the first somatostatin analogue used in the medical therapy of acromegaly, was initially given subcutaneously at doses of 100-500 microg three times daily. |
2004-06-01 |
2023-08-12 |
Not clear |
| G Vitale, R Pivonello, D Ferone, M C De Martino, R S Auriemma, M Caraglia, A Abbruzzese, G Lombardi, A Cola. The role of somatostatin receptors in the medical treatment of acromegaly. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. vol 36 Suppl 1. 2004-06-01. PMID:15077912. |
the treatment with somatostatin analogues induces biochemical control and tumour shrinkage in about 50-70% and 30-60% of patients with acromegaly, respectively. |
2004-06-01 |
2023-08-12 |
Not clear |
| John Ayuk, Susan E Stewart, Paul M Stewart, Michael C Sheppar. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical endocrinology. vol 60. issue 3. 2004-05-20. PMID:15009004. |
efficacy of sandostatin lar (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. |
2004-05-20 |
2023-08-12 |
Not clear |
| John Ayuk, Susan E Stewart, Paul M Stewart, Michael C Sheppar. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical endocrinology. vol 60. issue 3. 2004-05-20. PMID:15009004. |
somatostatin analogues have been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly for over 15 years, but debate surrounds their use as primary therapy. |
2004-05-20 |
2023-08-12 |
Not clear |
| Pamela U Fred. How effective are current therapies for acromegaly? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13 Suppl A. 2004-05-13. PMID:12914744. |
currently available therapies for acromegaly are transsphenoidal surgery (tss), radiotherapy (rt) and medical therapy with the dopamine agonists and somatostatin analogues. |
2004-05-13 |
2023-08-12 |
Not clear |
| Pamela U Fred. How effective are current therapies for acromegaly? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13 Suppl A. 2004-05-13. PMID:12914744. |
somatostatin analogues are the most effective medical therapy currently available for acromegaly. |
2004-05-13 |
2023-08-12 |
Not clear |
| Kate McKeage, Susan Cheer, Antona J Wagstaf. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. vol 63. issue 22. 2004-03-10. PMID:14609359. |
in the treatment of acromegaly, octreotide lar effectively controlled the secretion of gh and insulin-like growth factor-1 (igf-1) in about 55-70% of patients (n > 100) who had previously been treated with somatostatin analogues, a similar degree of control to that observed with subcutaneous octreotide and lanreotide slow release (sr). |
2004-03-10 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Alberto M Pereira, Marijke Frölich, Johannes A Romijn, Johannes D Veldhuis, Ferdinand Roelfsem. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American journal of physiology. Endocrinology and metabolism. vol 286. issue 1. 2004-02-12. PMID:14506078. |
in summary, chronic somatostatin agonism is able to repress amplitude-dependent measures of excessive gh secretion in acromegaly. |
2004-02-12 |
2023-08-12 |
Not clear |
| M Arosio, S Porretti, P Epaminonda, C Giavoli, C Gebbia, C Penati, P Beck-Peccoz, M Peracch. Elevated circulating somatostatin levels in acromegaly. Journal of endocrinological investigation. vol 26. issue 6. 2003-12-23. PMID:12952361. |
elevated circulating somatostatin levels in acromegaly. |
2003-12-23 |
2023-08-12 |
human |
| M Arosio, S Porretti, P Epaminonda, C Giavoli, C Gebbia, C Penati, P Beck-Peccoz, M Peracch. Elevated circulating somatostatin levels in acromegaly. Journal of endocrinological investigation. vol 26. issue 6. 2003-12-23. PMID:12952361. |
the aim of the present study was to characterize the fasting and postprandial pattern of plasma circulating somatostatin in normal subjects and patients with acromegaly. |
2003-12-23 |
2023-08-12 |
human |